Key result
Sorafenib monotherapy resulted in a sustained partial response over 60 months in a patient with unresectable hepatic epithelioid hemangioendothelioma.
Why the study?
Does sorafenib monotherapy improve tumor response in unresectable hepatic epithelioid hemangioendothelioma?
Case Report (n=1)
No
Does sorafenib monotherapy improve tumor response in unresectable hepatic epithelioid hemangioendothelioma?
Sorafenib monotherapy may provide long-term partial response in patients with unresectable hepatic epithelioid hemangioendothelioma.
May suggest sorafenib activity in this rare tumor; hypothesis-generating from Level 5 evidence and should not change practice.
A 49-year-old Japanese man had multiple huge masses (max. size 60 mm diameter) in his liver. These tumors were pathologically diagnosed by tumor biopsy as epithelioid hemangioendotheliomas of the liver. In this case, multiple liver tumors existed in both lobes. Also this patient did not agree to receive surgical resection including liver transplantation. Chemotherapy with sorafenib at a dose of 400 mg/body twice a day was started. About 6 months later, CT findings revealed that these tumors were shrinking slightly; 33 months later, the tumors obviously showed a partial response in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST). Also 60 months later, the partial response continued with sorafenib monotherapy.
No takes yet. Share an insight, caveat, or question.
Kobayashi et al. (2016) conducted a case report in Hepatic epithelioid hemangioendothelioma (n=1). Sorafenib was evaluated on Tumor response according to RECIST. Sorafenib monotherapy resulted in a sustained partial response over 60 months in a patient with unresectable hepatic epithelioid hemangioendothelioma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: